HCP EDUCATION

2518

Journeying Through the Spectrum of HER2 Expression Breast Cancer Clinic: Education Outcomes on Guiding Treatment Decisions




Authors: Tariqa Ackbarali, PhD, MS, CHCP[1]; Kia Jones, PhD[1]; Aditya Bardia, MD, MPH[2]; Sara Hurvitz, MD, FACP[3]

Affiliation: [1]MedliveCME, Needham, MA; [2]University of California, Los Angeles, Los Angeles, CA; [3]Fred Hutchinson Cancer Center, University of Washington, Seattle, WA

Support was provided by an independent educational grant from Daiichi Sankyo, Inc. and AstraZeneca Pharmaceuticals

INTRODUCTION




A significant change in practice has occurred in breast cancer based on an improved understanding of HER2 expression existing on a broader spectrum than previously known. Despite the availability of personalized treatments for patients with metastatic breast cancer (mBC) based on their HER2-expression status, many patients who express HER2 are not receiving the optimal, tailored treatment for their disease. This is largely due to a lack of clarity surrounding HER2 testing, integration of HER2-targeted therapies across all subtypes of breast cancer, and management of unique adverse events (AEs) associated with novel HER2-targeting therapies. An interactive case clinic was designed for oncology clinicians to engage in applying the latest guideline-recommended treatment approaches for mBC to close these gaps and ensure patients receive optimal therapy.

METHODOLOGY

Educational Program and Evaluation Details

Interventions



Data Collected

A survey-based approach measured the impact of the CME as aligned with stated learning objectives via pre- and post-activity knowledge/competence questions, as well as a post-activity evaluation (inclusive of intended practice changes: open-ended). Statistical tests of significance were applied to comparisons of individual questions (pre- vs post-activity).

RESULTS


Clinician education:

1,361
Total Participants
463 CME enduring
898 micro-learning


Micro-learning:

898
NPI-verified oncologists

Degree:




Specialty:




Educational impact


Average score (% correct) on 4-item test linked to learning objectives



Clinicians who were confident (rating of 4 or 5 on 5-point scale) treating mBC patients with HER2-low expression status with an anti-HER2 therapy



Pre-test variability in responses indicated that some learners were unclear on when additional testing is warranted, likely due to inconsistent application of updated HER2 testing protocols in clinical practice.



Send for FISH testing to confirm HER2 status

Intended learners - Oncology, Pathology

10 patients
Oncology- and pathology-based CME learners reported seeing an average of 10 patients with HER2+ mBC each week

89%
of CME learners completed the activity (311 learners, 276 completers)

Intended Practice Changes

Top 5 intended changes to clinical practice included:

	Percentage
Greater personalized treatment sequencing based on patient-specific characteristics	36%
Higher frequency of use of novel HER2-targeted agents in second-line therapy	29%
Implementation of stricter monitoring for AEs associated with HER2-targeted therapies	27%
Rigorous testing for HER2-low expression in patients with mBC	25%
Increased referrals for clinical trials of novel HER2-targeted agents	20%

CONCLUSION

Post-test gains indicated an improved ability among clinicians to differentiate between available antibody-drug conjugates (ADCs), with greater recognition of novel therapies as the preferred next-line therapy in HER2-low disease due to a targeted mechanism against HER2, even at low levels. However, persistent gaps suggest a need to reinforce how HER2-expression levels influence ADC selection and to clarify where other ADCs may fit into later-line treatment. Improvements were seen in testing protocols, treatment applications, and AE management for relevant populations most likely to benefit. Outcomes also demonstrated that the education helped clinicians focus on point-of-care decisions.